relaxin H2
Selected indexed studies
- Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. (Drug Discov Today, 2020) [PMID:32360533]
- H2 relaxin ameliorates angiotensin II-induced endothelial dysfunction through inhibition of excessive mitochondrial fission. (Biochem Biophys Res Commun, 2019) [PMID:30928096]
- Single-Shot Solid-Phase Synthesis of Full-Length H2 Relaxin Disulfide Surrogates. (Angew Chem Int Ed Engl, 2023) [PMID:36515186]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. (2020) pubmed
- H2 relaxin ameliorates angiotensin II-induced endothelial dysfunction through inhibition of excessive mitochondrial fission. (2019) pubmed
- Single-Shot Solid-Phase Synthesis of Full-Length H2 Relaxin Disulfide Surrogates. (2023) pubmed
- Production of human pro-relaxin H2 in the yeast Pichia pastoris. (2017) pubmed
- Post-stroke administration of H2 relaxin reduces functional deficits, neuronal apoptosis and immune cell infiltration into the mouse brain. (2023) pubmed
- H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. (2006) pubmed
- H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes. (2015) pubmed
- Relaxin family peptides: structure-activity relationship studies. (2017) pubmed
- Multi-Component Mechanism of H2 Relaxin Binding to RXFP1 through NanoBRET Kinetic Analysis. (2019) pubmed
- Single chain peptide agonists of relaxin receptors. (2019) pubmed